Highest-materiality recent filing
Q2 2026 net loss of $21.7M ($0.36/share) vs. $15.0M ($0.35/share) in Q2 2025.
Protara reports 68% six-month CR rate in TARA-002 trial; triggers warrant exercise period
Six-month complete response (CR) rate of 68.0% in 25 BCG-unresponsive NMIBC patients in Phase 2 ADVANCED-2 trial.
Protara Therapeutics Q4 net loss $17.3M; TARA-002 shows 68% CR in BCG-Unresponsive NMIBC
Net loss Q4 2025: $17.3M ($0.37/share); FY2025: $57.4M ($1.34/share).
TARA-002 shows 68% CR at 6 months in BCG-unresponsive NMIBC; no Grade 3+ TRAEs
BCG-Unresponsive cohort: CR rate 68.2% at 6 months (15/22), 33.3% at 12 months (5/15); 61.5% re-induction conversion.
Protara closes full underwriters' option, gross proceeds ~$86.3M from offering
Closed full exercise of underwriters' option for 1,956,521 shares at $5.75/share on Dec 15, 2025.
Protara Therapeutics prices public offering of 13M shares at $5.75 for $75M gross proceeds
Priced 13,043,479 common shares at $5.75 per share; gross proceeds ~$75M before fees.
Protara reports 72% CR for TARA-002 in BCG-Naïve NMIBC; FDA backs registrational path
CR at any time 72% (21/29); 69% at 6 months, 50% at 12 months in BCG-Naïve NMIBC.
Protara TARA-002 STARBORN-1: 100% clinical success in evaluable patients
8/8 evaluable patients (100%) achieved clinical success at eight-week assessment.
Protara Therapeutics Q3 net loss $13.3M; cash runway into mid-2027; key trial data readouts on track
Net loss of $13.3M ($0.31 per share) vs $11.2M ($0.50 per share) in Q3 2024.
Protara Q2 net loss $15M; cash $145.6M into mid-2027; key trial readouts set
Q2 2025 net loss $15.0M ($0.35/shr) vs $9.5M ($0.45/shr) in Q2 2024; R&D spend up to $10.8M.
Protara Therapeutics Q1 2025 net loss $11.9M; TARA-002 100% CR in BCG-Unresponsive cohort
Cash, cash equivalents and investments total $157.5M as of Mar 31, 2025; expected to fund operations into 2027.
Protara reports 100% CR at any time in BCG-unresponsive NMIBC; 67% at 12 months
BCG-Unresponsive: 100% CR at any time (5/5), 67% at 12 months (2/3) as of April 16, 2025 cutoff.
Protara Q4 net loss $12.8M, cash $170M; ADVANCED-2 12-month data by mid-2025
Cash and equivalents $170.3M as of Dec 31, 2024, funded into 2027 after $100M public offering.
Protara reports positive TARA-002 NMIBC data; expects key milestones in 2025; cash runway into 2027
TARA-002 in NMIBC: 72% CR at six months, 70% at any time; 100% maintained CR from 3 to 6 months; no Grade 2+ TRAEs.
Protara Therapeutics raises $100M in public offering to fund TARA-002 clinical development
Gross proceeds of ~$100M from offering of 13.69M shares and 2.33M pre-funded warrants at $6.25/share.
Protara TARA-002 shows 72% CR at 6 months in NMIBC Phase 2; 100% in BCG-unresponsive
72% (13/18) landmark complete response rate at 6 months across BCG exposures; 70% (14/20) at any time.
Protara Therapeutics reports Q3 2024 net loss of $11.2M; cash $81.5M; pipeline on track
Net loss $11.2M ($0.50 per share) vs $9.9M ($0.87) in Q3 2023; no revenue.
Protara Therapeutics Q2 net loss $9.5M; cash $89.6M; pipeline milestones on track
Net loss $9.5M ($0.45/share) vs $11.3M ($1.00/share) in Q2 2023; R&D expenses decreased to $6.4M.
Protara Therapeutics Q1 net loss $11.1M; cash runway into 2026 after $42M private placement
Q1 net loss $11.1M ($0.97/sh) vs $9.0M ($0.80/sh) YoY; R&D spend rose to $7.7M from $5.1M.
Private placement: gross proceeds ~$45M from 9.14M shares and 1.7M pre-funded warrants at $4.15; common warrants exercisable at $5.25.
Protara CMO Jathin Bandari resigns effective April 11; interim oversight assigned
CMO Jathin Bandari resigns effective April 11, 2024 to explore academic opportunities; consulting through July 11.
Protara reports Q4 net loss of $10.2M; cash $65.6M; TARA-002 data milestones in 2024
Net loss Q4 2023: $10.2M ($0.90/share); full-year net loss $40.4M ($3.57/share).
Protara Q3 net loss $9.9M; cash $74M; TARA-002 trials advance with results expected 1H24
Q3 2023 net loss of $9.9M ($0.87/shr) vs $7.7M ($0.68/shr) in Q3 2022.
Protara Q2 net loss $11.3M; TARA-002 trials on track; cash runway into 2025
Net loss Q2 2023: $11.3M ($1.00/share) vs $8.5M ($0.76) in Q2 2022
Protara reports Q1 net loss $9.0M; plans Phase 2 trials for TARA-002 in NMIBC and LMs
Cash, equivalents and restricted cash $89.5M at March 31, 2023; funding expected into 2025.
Protara reports positive Phase 1a data for TARA-002 in NMIBC; plans Phase 2 trial in 2H2023
TARA-002 well tolerated at all three doses; no dose-limiting toxicities; 40KE dose selected for further trials.
Protara confirms no material SVB exposure; cash runway into 2025 unchanged
$102.3M cash equivalents invested in short-term treasury/corporate bonds, not SVB.
Protara Q4 net loss $39.0M; cash $102.3M; TARA-002 data expected Q2 2023
Net loss Q4 2022: $39.0M ($3.46 per share) vs $10.2M ($0.91) in Q4 2021; includes $29.5M goodwill impairment.
Protara Q3 net loss $7.7M; cash $107.1M; TARA-002 trials progressing
Net loss of $7.7M ($0.68/share) vs. $10.8M ($0.96) in Q3 2021; includes $1.4M stock-based compensation.
Blaine Davis departed as CFO on July 15, 2022.
Protara Therapeutics CFO Blaine Davis to depart July 15, 2022
CFO Blaine Davis leaving to pursue other opportunities, effective July 15, 2022; resignation not due to disagreements.
Protara Therapeutics Q1 2022 net loss narrows to $10.8M; cash $118.5M funds into mid-2024
Net loss of $10.8M ($0.96/share) versus $13.5M ($1.20/share) in Q1 2021.
Protara Therapeutics reports Q4 net loss of $10.2M; cash $130.7M funds operations into mid-2024
Net loss for Q4 2021 was $10.2M ($0.91 loss per share); full year net loss $47.3M ($4.21 loss per share).
Protara Therapeutics CMO Departs; Jathin Bandari Named Interim CMO
Martín Sebastian Olivo, M.D., left as Chief Medical Officer effective Oct 15, 2021; will serve as consultant through Nov 22, 2021.
Protara Therapeutics receives FDA IND clearance for TARA-002 in non-muscle invasive bladder cancer
FDA cleared IND for TARA-002, an investigational cell-based therapy for NMIBC.
On March 18, 2024, Protara Therapeutics, Inc. (the “Company”) announced that Jathin Bandari, M.D., Chief Medical Officer of the Company, will be resigning from the Company to explore other opportunities, including devoting more time to academic work, effective as of April 11, 2024.
On January 30, 2023, Protara Therapeutics, Inc. (the “Company”) announced that, effective as of January 30, 2023, Patrick Fabbio had been appointed as Chief Financial Officer of the Company.
Mr. Fabbio will serve as the Company’s principal financial officer effective January 30, 2023, replacing Jesse Shefferman, the Company’s President and Chief Executive Officer, who had been serving in such role while the Company searched for a Chief Financial Officer.
Protara Therapeutics, Inc. (the “Company”) announced that Blaine Davis, the Chief Financial Officer of the Company, left the Company to pursue other opportunities on July 15, 2022.
Effective July 16, 2022 (the “Effective Date”), Hannah Fry has been appointed to the role of Controller of the Company.
Also effective July 16, 2022, Mr. Shefferman has been appointed as principal financial officer of the Company.
On June 21, 2022 Protara Therapeutics, Inc. (the “Company”) announced that Blaine Davis, Chief Financial Officer of the Company, will be leaving the Company to pursue other opportunities effective as of July 15, 2022.
Effective as of January 10, 2022 (the “Effective Date”), Protara Therapeutics, Inc. (the “Company”) appointed Jathin Bandari, M.D. as Chief Medical Officer of the Company.
Effective October 15, 2021, Martín Sebastian Olivo, M.D. will no longer be employed by the Company as Chief Medical Officer
Max materiality 0.85 · Median 0.60 · Most common event earnings